Market share of generics in European countries 2016

Market share of generics in selected European countries as of 2016

Market share of generics in European countries 2016 This statistic displays the share of generics in the pharmaceutical market sales value in Europe by selected countries in 2016. The generic share in the pharmaceutical industry's market sales in Denmark exceeded 30 percent in 2016. Market share of generics is higher in newer EU member states due to low levels of intellectual property protection.
Show more

Market share of generics in selected European countries as of 2016

Loading statistic...
Expand statistic
Share of pharmaceutical market sales value
Poland60.4%
Russia57%
Italy56.1%
Bulgaria47%
Croatia42%
Austria40.6%
Turkey39.2%
Hungary37.6%
Germany30.8%
Denmark30.5%
United Kingdom29%
Romania28.1%
Slovenia25.5%
Finland24.2%
Greece23.4%
Spain22.1%
Portugal22%
France19.6%
Ireland19%
Estonia18.9%
Sweden18.6%
Netherlands17.2%
Belgium16.6%
Switzerland13.5%
Share of pharmaceutical market sales value
Poland60.4%
Russia57%
Italy56.1%
Bulgaria47%
Croatia42%
Austria40.6%
Turkey39.2%
Hungary37.6%
Germany30.8%
Denmark30.5%
United Kingdom29%
Romania28.1%
Slovenia25.5%
Finland24.2%
Greece23.4%
Spain22.1%
Portugal22%
France19.6%
Ireland19%
Estonia18.9%
Sweden18.6%
Netherlands17.2%
Belgium16.6%
Switzerland13.5%
Download Settings Share
Chart type
Datalabels
Share on Social Media
HTML code to embed chart as PNG (FAQ)
Download started
Please be patient - this may take a moment

Description

Source

More information

This statistic displays the share of generics in the pharmaceutical market sales value in Europe by selected countries in 2016. The generic share in the pharmaceutical industry's market sales in Denmark exceeded 30 percent in 2016. Market share of generics is higher in newer EU member states due to low levels of intellectual property protection.
Show more
Release date
June 2018
Region
Europe
Survey time period
2016
Supplementary notes
EFPIA: European Federation of Pharmaceutical Industries and Associations
Croatia, Denmark, Estonia, Finland, Greece, United Kingdom: share of generics in pharmacy market sales. Austria, Belgium, Bulgaria, France, Germany, Ireland, Italy, Netherlands, Portugal, Slovenia, Spain: share of generics in reimbursable pharmacy market sales. Czech Republic, Poland, Romania, Russia, Sweden, Switzerland, Turkey: share of generics in total market sales. Cyprus, Hungary, Iceland, Latvia, Lithuania, Malta, Norway, Serbia, Slovakia: 2016 data not available. France: data relate only to those active substances listed on the official list of medicines.
Statista Accounts: Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
paypalgoogleadobepgsamsungtelekom
Related Studies: Available to Download in PDF or PPTX Format
Pharmaceutical trends in Europe
Pharmaceutical trends in Europe

All Information
in one Presentation

Pharmaceutical trends in Europe

Everything On "Pharmaceutical trends in Europe" in One Document: Edited and Divided into Handy Chapters. Including Detailed References.

Statista is a great source of knowledge, and pretty helpful to manage the daily work.
Christof Baron

Christof Baron
CEO, MindShare Germany

Statistics on "Pharmaceutical trends in Europe"
  • Overview
The most important statistics
  • European Pharmaceutical companies
  • Self-medication market
  • Employment
  • Clinical Trials
Need help with using Statista for your research? Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Learn more about how Statista can support your business.
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.